The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications
Authors:
- 31 December 2008
- journal article
- review article
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 26 (3) , 215-227
Abstract
MTA (metastasis-associated gene) is a newly discovered family of cancer progression-related genes and their encoded products. MTA1, the first gene found in this family, has been repeatedly reported to be overexpressed along with its protein product MTA1 in a wide range of human cancers. In addition, the expression of MTA1/MTA1 correlates with the clinicopathological properties (malignant properties) of human cancers. MTA proteins are transcriptional co-repressors that function in histone deacetylation and are involved in the NuRD complex, which contains nucleosome remodeling and histone deacetylating molecules. MTA1 expression correlates with tumor formation in the mammary gland. In addition, MTA1 converts breast cancer cells to a more aggressive phenotype by repression of the estrogen receptor (ER) α trans-activation function through deacetylation of the chromatin in the ER-responsive element of ER-responsive genes. Furthermore, MTA1 plays an essential role in c-MYC-mediated cell transformation. Another member of this family, MTA3, is induced by estrogen and represses the expression of the transcriptional repressor Snail, a master regulator of “epithelial to mesenchymal transitions”, resulting in the expression of the cell adhesion molecule E-cadherin and maintenance of a differentiated, normal epithelial phenotype in breast cells. In addition, tumor suppressor p53 protein is deacetylated and inactivated by both MTA1 and MTA2, leading to inhibition of growth arrest and apoptosis. Moreover, a hypoxia-inducible factor-1α (HIF-1α) is also deacetylated and stabilized by MTA1, resulting in angiogenesis. Thus, MTA proteins, especially MTA1, represent a possible set of master co-regulatory molecules involved in the carcinogenesis and progression of various malignant tumors. MTA proteins are proposed to be important new tools for clinical application in cancer diagnosis and treatment.Keywords
This publication has 87 references indexed in Scilit:
- Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinomaHepatology, 2008
- Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cellsOncogene, 2008
- MTA1-mediated transcriptional repression of BRCA1 tumor suppressor geneOncogene, 2007
- Repression of Six3 by a corepressor regulates rhodopsin expressionProceedings of the National Academy of Sciences, 2007
- MTA family of coregulators in nuclear receptor biology and pathologyNuclear Receptor Signaling, 2007
- Metastatic tumor antigen 3 is a direct corepressor of the Wnt4 pathwayGenes & Development, 2006
- Genetic Differentiation of Appendiceal Tumor MalignancyAnnals of Surgery, 2006
- MTA1, a transcriptional activator of breast cancer amplified sequence 3Proceedings of the National Academy of Sciences, 2006
- Reduced MTA1 Expression by RNAi Inhibits in Vitro Invasion and Migration of Esophageal Squamous Cell Carcinoma Cell LineClinical & Experimental Metastasis, 2005
- Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapiesBreast Cancer Research and Treatment, 2005